ArticleArchives of microbiology2026
Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antibiotic resistance has significantly constricted the therapeutic efficacy of antibiotics on treating bacterial infections, creating an urgent need for new antimicrobial agents. However, progress in developing these agents is slow, prompting the exploration of innovative strategies such as combination therapy. This study examined the combined effects of Temporin antimicrobial peptides with antibiotics against Escherichia coli and Pseudomonas aeruginosa. We found that Temporin-GHaR (GHaR) and Temporin-GHaK (GHaK) with polymyxin B (PMB) showed synergistic antibacterial activity against P. aeruginosa and E. coli, with a fractional inhibitory concentration index (FICI) below 0.5. Further mechanistic studies revealed that the combination of GHaR/GHaK with PMB significantly enhanced the bactericidal effect by synergistically augmenting the disruption of the outer and inner membranes of P. aeruginosa and E. coli. Meanwhile, this combination regimen demonstrated efficacy in inhibiting the biofilm formation of P. aeruginosa and E. coli at concentrations lower than those required for single-drug treatments, and enhanced the disruption of mature E. coli biofilms. The synergistic use of GHaR/GHaK and PMB augmented the antibacterial efficacy against P. aeruginosa and E. coli without increasing hemolytic toxicity to murine erythrocytes. These findings provide an experimental foundation and theoretical framework for the application of conventional antimicrobial agents.
Indexed as
Identifiers
41724849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.